Advertisement
"Mike is a terrific addition to our board," said Cequent President andCEO, Peter Parker. "With more than 20 years in the pharmaceutical industry,his extensive experience ranges from drug discovery -- leading early andlate-stage development projects across multiple therapeutic areas, includingLipitor(R) and Neurontin(R) -- to licensing, business development, andmanaging R&D alliances with pharmaceutical and biotech partners. His counseland strong industry relationships will be valuable assets to Cequent as wecontinue to move our clinical candidates from pre-clinical development towarda successful IND submission with the FDA."
Advertisement
Dr. Taylor joined Ensemble Discovery Corporation in July of 2007.Previously, he was senior vice president for Pfizer's Global R&D division. Inaddition to his R&D experience, he is active in investor development,government affairs, and public policy affecting the pharmaceutical industry.Until 2003, he was adjunct professor of medicinal chemistry at the College ofPharmacy at the University of Michigan, where he was active in teachingmedicinal chemistry and biopharmaceutics. Dr. Taylor has authored orcoauthored 65 manuscripts and published abstracts, and holds six patents.
Dr. Taylor has a doctorate in medicinal chemistry from the StateUniversity of New York at Buffalo and was awarded an NIH postdoctoralfellowship in natural products synthesis and structure elucidation at theUniversity of Pennsylvania.
About Cequent Pharmaceuticals, Inc.
An early-stage biopharmaceutical company, Cequent is pioneering thedevelopment of novel therapeutics to prevent and treat a wide range of humandiseases -- from inflammatory diseases to cancer -- based on the company'sproprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent'sfirst products, now in pre-clinical development, are drug candidates targetingcolon-cancer prevention and inflammatory bowel disease. The company designedits powerful tkRNAi technology to deactivate specific disease-causing genessafely and effectively, using non-pathogenic bacteria as an engine to produceand deliver RNAi directly into cells. It is based on ground-breakingscientific research originating at the Beth Israel Deaconess MedicalCenter/Harvard Medical School. A privately held company based in Cambridge,Massachusetts, Cequent was established in 2006. For more information, visithttp://www.cequentpharma.com.
SOURCE Cequent Pharmaceuticals, Inc.
